Company Profile

Immunomedics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. It has a pipeline of six clinical-stage product candidates. Its portfolio of investigational products includes antibody-drug conjugates (ADCs) that are designed to deliver a payload of a chemotherapeutic directly to the tumor, while the managing overall toxic effects that are found with conventional administration of these chemotherapy agents. Its ADCs are sacituzumab govitecan (IMMU-132) and labetuzumab govitecan (IMMU-130). The Company also has a range of other product candidates that target solid tumors and hematologic malignancies, as well as other diseases, in various-stages of clinical and pre-clinical development.

Employees

Sector

Biotechnology & Medical Research

More about the company

12-15	Immunome jumps after promising results for its desmoid tumor treatment
23-03-26	Everest Medicines Limited announced that it has received $280 million in funding from Immunomedics, Inc.	CI
21-01-11	Gilead Sciences : Raises Product Sales Guidance on Remdesivir Demand, Narrows Earnings Outlook for 2020	DJ
20-12-10	Gilead Sciences : to Pay $1.4 Billion for Hepatitis Drug Maker MYR GmbH of Germany	DJ
20-10-28	Gilead Sciences : Quarterly Revenue Rises on Remdesivir Sales -- Update	DJ
20-10-28	Gilead Sciences : Quarterly Revenue Rises on Remdesivir Sales	DJ
20-10-23	Immunomedics, Inc. Announces Board Changes	CI
20-10-23	Immunomedics, Inc.(NasdaqGM:IMMU) dropped from S&P Biotechnology Select Industry Index	CI
20-10-23	Immunomedics, Inc.(NasdaqGM:IMMU) dropped from S&P Global BMI Index	CI
20-10-23	Immunomedics, Inc.(NasdaqGM:IMMU) dropped from S&P TMI Index	CI
20-10-23	Immunomedics, Inc.(NasdaqGM:IMMU) dropped from Russell 1000 Index	CI
20-10-23	Immunomedics, Inc.(NasdaqGM:IMMU) dropped from Russell Midcap Index	CI
20-10-23	Immunomedics, Inc.(NasdaqGM:IMMU) dropped from Russell 1000 Growth Index	CI

23-03-27	Everest Medicines Receives Full Upfront Payment from Gilead for Trodelvy-Related Transaction, Boosting Pro Forma Cash Reserves	AQ
22-08-16	Gilead to Acquire Remaining Worldwide Rights of Trodelvy	AQ
21-04-20	Protara Therapeutics : Announces Appointment of Martin Sebastian Olivo, M.D. as Chief Medical Officer	AQ
20-12-11	Gilead Sciences : Advances Oncology Portfolio with New Data from Phase 3 ASCENT Trial of Trodelvy in Metastatic Triple Negative Breast Cancer	AQ
20-10-29	Gilead Sciences : Announces Third Quarter 2020 Financial Results	AQ

12-15	Immunome bondit après des résultats prometteurs pour son traitement contre les tumeurs desmoïdes
21-02-05	La banque d'affaires Lazard a vu bondir son bénéfice net en 2020
20-10-23	BB Biotech sombre dans le rouge au 3e trimestre, reste à flot sur 9 mois
20-10-23	HBM im Halbjahr 2020/21 mit Gewinnsprung - Zuversichtlich ins zweite Halbjahr
20-09-14	Aktien New York Schluss: Übernahmen bescheren starken Wochenauftakt

Manager	Title	Age	Since
Christina Carlson PRN	Corporate Officer/Principal	-	2020-10-22
Brett Pletcher SEC	Corporate Secretary	58	2020-10-22

Director	Title	Age	Since
Brett Pletcher BRD	Director/Board Member	58	2020-10-22
Christina Carlson BRD	Director/Board Member	-	2020-10-22
Robert Musslewhite BRD	Director/Board Member	56	2019-12-31

Immunomedics, Inc. Stock

Stocks

IMMU

US4529071080

Biotechnology & Medical Research

Latest news : Immunomedics, Inc.

Press Releases: Immunomedics, Inc.

News in other languages: Immunomedics, Inc.

Quotes and Performance

Managers and Directors: Immunomedics, Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Company Profile

Date	Insider	Type	Main position	Quantity	% Market Cap.
10/23/20	Brendan Delaney	Issuer sale	Executive/Senior Manager	390,460	0.1689%
10/23/20	Khalid Islam	Issuer sale	Director	69,848	0.0302%
10/23/20	Jared M. Freedberg	Issuer sale	General Counsel	280,105	0.1212%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
IMMUNOMEDICS, INC.	+0.05%	+0.34%	-	-	20.32B
LONZA GROUP AG	+1.07%	-3.49%	-3.25%	+12.87%	46.86B
REVOLUTION MEDICINES, INC.	+0.25%	+1.65%	+408.41%	+629.49%	40.23B
BEONE MEDICINES AG	-0.27%	+4.45%	+9.93%	+66.92%	36.23B
IQVIA HOLDINGS INC.	+0.35%	+0.87%	+3.60%	-8.81%	34.72B
CELLTRION, INC.	+3.14%	+1.02%	+3.37%	+38.15%	27.89B
MEDPACE HOLDINGS, INC.	-0.73%	+11.84%	+31.97%	+143.53%	16.79B
ASCENDIS PHARMA A/S	+0.47%	-2.74%	-	-	16.74B
EUROFINS SCIENTIFIC SE	+0.42%	-5.52%	+0.76%	+8.50%	13.12B
ICON PUBLIC LIMITED COMPANY	-2.68%	-2.49%	-15.00%	-31.68%	12.7B
Average	+0.21%	+0.83%	+54.97%	+107.37%	27.25B
Weighted average by Cap.	+0.45%	+0.91%	+75.32%	+136.64%